Benda Pharmaceutical, Inc (BPMA.OB), a China-based pharmaceutical company that produces traditional Chinese and conventional medicines, announced that the company has entered into a financial advisory agreement with CRT Capital Group LLC. According to the terms discussed in this agreement, CRT will assist Benda in evaluating their strategic and financial corporate alternatives, including joint ventures, spin-offs, financing, or other capital market transactions.
Furthermore, Benda has also entered into a financial advisory agreement with EastGate Financial, Inc. EastGate will help Benda apply for a listing on the American Stock Exchange and help Benda identify and choose an AMEX specialist firm.
Yiqing Wan, CEO of Benda Pharmaceutical, commented, “Entering into these new strategic relationships with CRT and EastGate is a watershed moment in our development into a leading pharmaceutical company, both in China and beyond. CRT and EastGate both have deep experience in our space, and CRT’s demonstrated success in helping evolve one of our closest peer companies, American Oriental Bioengineering (NYSE: AOB), gives us the utmost confidence that the relationship will help us achieve each of our operational and financial goals.”
Let us hear your thoughts below:
